DA32 Life Science Tech Acquisition Corp. (DALS) financial statements (2022 and earlier)

Company profile

Business Address 345 PARK AVENUE SOUTH
NEW YORK, NY 10010
State of Incorp. DE
Fiscal Year End December 31
SIC 677 - Blank Checks (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,865
Cash and cash equivalents1,865
Prepaid expense603
Total current assets:2,468
Noncurrent Assets
Assets held-in-trust200,025
Total noncurrent assets:200,025
TOTAL ASSETS:202,493
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities287
Accrued liabilities144
Taxes payable143
Total current liabilities:287
Noncurrent Liabilities
Other undisclosed noncurrent liabilities5,600
Total noncurrent liabilities:5,600
Total liabilities:5,887
Temporary equity, carrying amount200,000
Stockholders' equity
Stockholders' equity attributable to parent, including:(3,394)
Accumulated deficit(3,394)
Other undisclosed stockholders' equity attributable to parent1
Total stockholders' equity:(3,394)
TOTAL LIABILITIES AND EQUITY:202,493

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: